OBJECTIVES: To estimate the probability of survival and to evaluate risk factors for death in a cohort of persons living with human immunodeficiency virus (PLHIV) who had started tuberculosis (TB) treatment. METHODS: A prospective cohort study was conducted between June 2007 and December 2009 with HIV-infected patients who had started anti-tuberculosis treatment in the State of Pernambuco, Brazil. Survival data were analysed using the Kaplan-Meier estimator, the log-rank test and the Cox model. Hazard ratios and their respective 95%CIs were estimated. RESULTS: Of a cohort of 2310 HIV-positive individuals, 333 patients who had commenced treatment for TB were analysed. The mortality rate was 5.25 per 10,000 person-years (95%CI 4.15-6.63). The probability of survival at 30 months was 74%. Risk factors for death in the study population were being female, age ≥30 years, having anaemia, not using highly active antiretroviral therapy (HAART) during treatment for TB and disseminated TB. Protective factors for death were a CD4 lymphocyte count >200 cells/mm(3) and treatment for TB having started in an out-patient clinic. CONCLUSIONS: The use of HAART can prevent deaths among HIV-TB patients, corroborating the efficacy of starting HAART early in individuals with TB.
OBJECTIVES: To estimate the probability of survival and to evaluate risk factors for death in a cohort of persons living with human immunodeficiency virus (PLHIV) who had started tuberculosis (TB) treatment. METHODS: A prospective cohort study was conducted between June 2007 and December 2009 with HIV-infectedpatients who had started anti-tuberculosis treatment in the State of Pernambuco, Brazil. Survival data were analysed using the Kaplan-Meier estimator, the log-rank test and the Cox model. Hazard ratios and their respective 95%CIs were estimated. RESULTS: Of a cohort of 2310 HIV-positive individuals, 333 patients who had commenced treatment for TB were analysed. The mortality rate was 5.25 per 10,000 person-years (95%CI 4.15-6.63). The probability of survival at 30 months was 74%. Risk factors for death in the study population were being female, age ≥30 years, having anaemia, not using highly active antiretroviral therapy (HAART) during treatment for TB and disseminated TB. Protective factors for death were a CD4 lymphocyte count >200 cells/mm(3) and treatment for TB having started in an out-patient clinic. CONCLUSIONS: The use of HAART can prevent deaths among HIV-TBpatients, corroborating the efficacy of starting HAART early in individuals with TB.
Authors: Alexandre Grangeiro; Maria Mercedes Escuder; Alex Jones Flores Cassenote; Alex Jones Flores Cassanote; Rosa Alencar Souza; Artur O Kalichman; Valdiléa G Veloso; Valdiléa Veloso; Maria Letícia Rodrigues Ikeda; Nêmora Tregnago Barcellos; Carlos Brites; Unai Tupinanbás; Noaldo O Lucena; Carlos Lima da Silva; Heloisa Ramos Lacerda; Beatriz Grinsztejn; Euclides Ayres Castilho Journal: PLoS One Date: 2014-05-01 Impact factor: 3.240
Authors: R Cunha; M Maruza; U R Montarroyos; I Coimbra; D de B Miranda-Filho; M de F Albuquerque; H R Lacerda; Raa Ximenes Journal: BMC Infect Dis Date: 2017-02-10 Impact factor: 3.090
Authors: Gabriela Tavares Magnabosco; Lívia Maria Lopes; Rubia Laine de Paula Andrade; Maria Eugênia Firmino Brunello; Aline Aparecida Monroe; Tereza Cristina Scatena Villa Journal: Rev Lat Am Enfermagem Date: 2016-09-09